Ann: Opthea Announces MST Conference call with Jason Slakter MD, page-14

No problem with reposting elsewhere. The principles outlined in essence apply to all biotech companies going through regulatory processes involving drug trials and/or seeking approval to bring a new therapeutic, or device to market.
Successful emerging biotech companies look well ahead (at least 2 years) at what their likely needs are going to be in terms of staffing and relevant infrastructure resources. This goes hand in hand with having the financial resources to action their plan. Biotech companies making and taking opportunities to raise capital before they really need it is important. Retail shareholders in particular inevitably get the short end of the stick when a biotech company reaches a position where it is forced to go to the market to raise money.